Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds

More articles from Oncology, Clinical Science Track

  • You have access
    Baseline Metabolic Tumor Volume predicts outcome in patients with high tumor burden follicular lymphoma.
    Anne Segolene Cottereau, Annibale Versari, Jehan Dupuis, Loic Chartier, Ilaria Grassi, Stephanie Becker, Corinne Haioun, Stefano Luminari, Michel Meignan and Judith Trotman
    Journal of Nuclear Medicine May 1, 2016, 57 (supplement 2) 30;
  • You have access
    Curative theranostic pretargeted radioimmunotherapy (PRIT) of GPA33-expressing colorectal cancer (CRC) using a bispecific antibody with high affinity for GPA33 and DOTA (D) metal complex (DPRIT).
    Sarah Cheal, Hong Xu, Hong-fen Guo, Miteshkumar Patel, Blesida Punzalan, Edward Fung, Pat Zanzonico, K Dane Wittrup, Nai-Kong Cheung and Steven Larson
    Journal of Nuclear Medicine May 1, 2016, 57 (supplement 2) 33;
  • You have access
    Direct comparison of 68Ga-DOTA-TOC and 18F-FDG-PET/CT in the follow-up of neuroendocrine tumor patients treated with first full peptide receptor radionuclide therapy
    Irene Virgolini, Bernhard Nilica, Dietmar Waitz, Vlado Stevanovic, Christian Uprimny, Dorota Kendler, Sabine Buxbaum, Boris Warwitz, Llanos Gerardo, Benjamin Henninger and Margarida Rodrigues
    Journal of Nuclear Medicine May 1, 2016, 57 (supplement 2) 24;
  • You have access
    Impact of Gallium-68-DOTA-NOC PET/CT on Management Of Neuroendocrine tumors
    Charu Jora
    Journal of Nuclear Medicine May 1, 2016, 57 (supplement 2) 23;
  • You have access
    High diagnostic value of FDG-PET/CT in endometrial cancer: Systematic review and meta-analysis of the literature.
    Vikram Rao Bollineni
    Journal of Nuclear Medicine May 1, 2016, 57 (supplement 2) 76;
  • You have access
    Role of FDG PET/CT in staging of early carcinoma cervix
    Satyavrat Verma, SWATI SWATI, RAKESH KUMAR, SUNESH KUMAR, CHETAN PATEL, VARUN DHULL, BISWAJIT SAHOO, MADHAVI TRIPATHI, S SHAMIM, NISHIKANT DAMLE, DHIRENDRA JAISWAL, GANESH KUMAR and C BAL
    Journal of Nuclear Medicine May 1, 2016, 57 (supplement 2) 81;

Pages

  • Previous
  • 1
  • …
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
SNMMI

© 2025 SNMMI

Powered by HighWire